Skip to main content
. 2012 Feb 15;2:13. doi: 10.3389/fonc.2012.00013

Figure 2.

Figure 2

Phase 3 pivotal trial (AXIS and TIVO-1) designs for studies of axitinib or tivozanib vs sorafenib.